Valeant Pharmaceuticals Intl Company Profile (NYSE:BVF)

About Valeant Pharmaceuticals Intl (NYSE:BVF)

Valeant Pharmaceuticals Intl logoValeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NYSE:BVF
  • CUSIP: N/A
  • Web: www.valeant.com/
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: N/A
Dividend:
  • Dividend Yield: 1.0%
Profitability:
  • Net Margins: -1.66%
  • Return on Equity: -3.90%
  • Return on Assets: -0.35%
 

Frequently Asked Questions for Valeant Pharmaceuticals Intl (NYSE:BVF)

What is Valeant Pharmaceuticals Intl's stock symbol?

Valeant Pharmaceuticals Intl trades on the New York Stock Exchange (NYSE) under the ticker symbol "BVF."

Who are some of Valeant Pharmaceuticals Intl's key competitors?

Who are Valeant Pharmaceuticals Intl's key executives?

Valeant Pharmaceuticals Intl's management team includes the folowing people:

  • Joseph C. Papa, Chairman of the Board, Chief Executive Officer
  • Paul S. Herendeen, Chief Financial Officer, Executive Vice President
  • Christina Ackermann, Executive Vice President, General Counsel
  • Thomas J. Appio, Executive Vice President, Company Group Chairman, International
  • William D. Humphries, Executive Vice President, Company Group Chairman, Dermatology
  • Thomas W. Ross Sr, Lead Independent Director
  • Richard U. DeSchutter, Independent Director
  • Fredric N. Eshelman Pharm.D., Ph.D., Independent Director
  • D. Robert Hale, Independent Director
  • Argeris N. Karabelas Ph.D., Independent Director

How do I buy Valeant Pharmaceuticals Intl stock?

Shares of Valeant Pharmaceuticals Intl can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.


MarketBeat Community Rating for Valeant Pharmaceuticals Intl (NYSE BVF)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  55 (Vote Outperform)
Underperform Votes:  46 (Vote Underperform)
Total Votes:  101
MarketBeat's community ratings are surveys of what our community members think about Valeant Pharmaceuticals Intl and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Valeant Pharmaceuticals Intl (NYSE:BVF) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Valeant Pharmaceuticals Intl (NYSE:BVF)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Valeant Pharmaceuticals Intl (NYSE:BVF)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Valeant Pharmaceuticals Intl (NYSE:BVF)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Valeant Pharmaceuticals Intl (NYSE:BVF)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Valeant Pharmaceuticals Intl (NYSE:BVF)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Valeant Pharmaceuticals Intl (NYSE:BVF)
Latest Headlines for Valeant Pharmaceuticals Intl (NYSE:BVF)
Source:
DateHeadline
feeds.benzinga.com logoWhat You Should Know About The Drug Approval Valeant Could Receive This Week
feeds.benzinga.com - September 18 at 11:19 AM
nasdaq.com logoChou RRSP Fund Buys Valeant Pharmaceuticals International Inc, EXCO Resources Inc, Sells ...
www.nasdaq.com - September 13 at 5:59 PM
investorplace.com logoValeant Pharmaceuticals Intl Inc (VRX) Stock Is STILL Too Ugly to Buy
investorplace.com - September 12 at 9:20 AM
bizjournals.com logoQuébec Superior Court Grants Leave under Québec Securities Act in Valeant Pharmaceuticals Securities Class Action
www.bizjournals.com - September 6 at 4:49 PM
fool.ca logo4 Reasons Valeant Pharmaceuticals Intl Inc. Might Be a Good Investment Today
www.fool.ca - September 6 at 4:49 PM
zacks.com logoValeant (VRX) Continues to Lose Ground: Can It Bounce Back?
www.zacks.com - September 2 at 3:09 AM
globenewswire.com logoProgenics Pharmaceuticals Presents Data from AZEDRA® Pivotal Phase 2b Study at the 5th International Symposium on Pheochromocytoma and Paraganglioma
globenewswire.com - August 31 at 4:42 PM
benzinga.com logoThere's No Fundamental Reason For Valeant Shares To Be Down
www.benzinga.com - August 30 at 6:08 PM
nasdaq.com logoValeant Pharmaceuticals International Becomes Oversold (VRX)
www.nasdaq.com - August 29 at 5:12 PM
investorplace.com logoWhy Finish Line Inc (FINL), Valeant Pharmaceuticals Intl Inc (VRX) and Best Buy Co Inc (BBY) Are 3 of Today’s Worst Stocks
investorplace.com - August 29 at 4:45 PM
theglobeandmail.com logoValeant faces potentially costly securities fraud lawsuit in U.S.
www.theglobeandmail.com - August 25 at 6:34 PM
investorplace.com logoWhy Ulta Beauty Inc (ULTA), Valeant Pharmaceuticals Intl Inc (VRX) and GameStop Corp. (GME) Are 3 of Today’s Worst Stocks
investorplace.com - August 25 at 4:53 PM
feeds.benzinga.com logoWhat's The FDA Saying About Valeant's Manufacturing Facility Issues?
feeds.benzinga.com - August 21 at 10:21 AM
fool.ca logoWhy an Investment in Valeant Pharmaceuticals Intl Inc. Needs to Be Long Term
www.fool.ca - August 18 at 4:56 PM
seekingalpha.com logoValeant Pharmaceuticals International, Inc. 2017 Q2 - Results - Earnings Call Slides
seekingalpha.com - August 18 at 4:56 PM
rttnews.com logoValeant Receives FDA Confirmation Of VAI Inspection For Tampa Facility
www.rttnews.com - August 17 at 11:12 PM
benzinga.com logoValeant's CEO Details The Company's 'Great Progress' And What's Next
www.benzinga.com - August 17 at 6:09 PM
247wallst.com logoValeant Pharmaceuticals Gets Boost From FDA Update
247wallst.com - August 17 at 6:09 PM
fool.ca logoValeant Pharmaceuticals Intl Inc.: Still a Risk or on the Way up?
www.fool.ca - August 17 at 6:09 PM
marketwatch.com logoValeant Pharma works to resolve FDA concerns at Tampa plant
www.marketwatch.com - August 17 at 3:23 AM
marketwatch.com logoValeant Receives FDA Confirmation Of Voluntary Action Indicated (VAI) Inspection Classification For Tampa Facility
www.marketwatch.com - August 16 at 10:21 PM
investorplace.com logoThe Bull Case for Valeant Pharmaceuticals Intl Inc (VRX) Stock Is Weak
investorplace.com - August 16 at 10:32 AM
fool.ca logoHow Rising Rates May Bankrupt Valeant Pharmaceuticals Intl Inc.
www.fool.ca - August 14 at 10:18 PM
marketwatch.com logoPaulson & Co., Inc. Reiterates Confidence In Valeant Strategy
www.marketwatch.com - August 9 at 10:00 PM
investorplace.com logoValeant Pharmaceuticals Intl Inc (VRX) Stock Scores 2 Vital Victories
investorplace.com - August 8 at 11:00 AM
investorplace.com logoTuesday’s Vital Data: Apple Inc. (AAPL), Alibaba Group Holding Ltd (BABA) and Valeant Pharmaceuticals Intl Inc (VRX)
investorplace.com - August 8 at 9:58 AM
prnewswire.com logoValeant Pharmaceuticals Receives Complete Response Letter from the FDA for ...
www.prnewswire.com - August 7 at 5:17 PM
investorplace.com logoHow Valeant Pharmaceuticals Intl Inc (VRX) Stock Can Make a Comeback
investorplace.com - August 7 at 10:00 AM
nasdaq.com logo3 Things You'll Want to Watch in Valeant Pharmaceuticals' Q2 Results
www.nasdaq.com - August 6 at 4:13 PM
investorplace.com logoValeant Pharmaceuticals Intl Inc (VRX) Stock: Stupid Is as Stupid Does
investorplace.com - August 4 at 2:30 PM
investorplace.com logo3 Big Stock Charts for Friday: GoPro Inc (GPRO), Valeant Pharmaceuticals Intl Inc (VRX) and Microchip Technology Inc. (MCHP)
investorplace.com - August 4 at 1:53 PM
investorplace.com logoShould You Buy Valeant Pharmaceuticals Intl Inc (VRX) Stock? 3 Pros, 3 Cons
investorplace.com - July 24 at 1:16 PM
investorplace.com logoValeant Pharmaceuticals Intl Inc (VRX) Stock Is Back From the Abyss
investorplace.com - July 21 at 10:05 AM
fool.ca logoValeant Pharmaceuticals Intl Inc.: Is it Comeback Time?
www.fool.ca - July 20 at 6:32 PM
fool.ca logoValeant Pharmaceuticals Intl Inc. Will Do Almost Anything to Lower Debt
www.fool.ca - July 19 at 11:03 PM
baystreet.ca logoAs Valeant Approaches Its $5-Billion Debt Reduction Goal, Is Now the Time to Buy?
www.baystreet.ca - July 18 at 6:17 PM
marketwatch.com logoValeant is meeting its debt goals, but core business is still struggling
www.marketwatch.com - July 17 at 5:11 PM
reuters.com logoValeant to sell Obagi Medical Products business for $190 million
www.reuters.com - July 17 at 5:11 PM
seekingalpha.com logoValeant: At Worst, A Good Catalyst Play
seekingalpha.com - July 17 at 5:11 PM
investorplace.com logoValeant Pharmaceuticals Intl Inc (VRX) Stock Is No Longer a “Sewer”
investorplace.com - July 13 at 10:51 AM
fool.ca logoWhy Is Valeant Pharmaceuticals Intl Inc. up 30% Since June 1?
www.fool.ca - July 11 at 5:49 PM
marketwatch.com logoValeant Announces Q2 2017 Financial Results Date And Conference Call Details
www.marketwatch.com - July 11 at 2:53 AM
fool.ca logoValeant Pharmaceuticals Intl Inc. With Papa Is a Great Buy
www.fool.ca - July 11 at 2:53 AM
investorplace.com logoValeant Pharmaceuticals Intl Inc (VRX) Stock Is Seeing a Lot of Quiet Buying
investorplace.com - July 10 at 12:28 PM
investorplace.com logoWhy Valeant Pharmaceuticals Intl Inc (VRX) Stock Is Untouchable
investorplace.com - June 29 at 9:19 AM
fool.ca logoWhat’s the Next Stop for Valeant Pharmaceuticals Intl Inc.?
www.fool.ca - June 27 at 4:20 PM
nasdaq.com logoValeant Pharmaceuticals International Reaches Analyst Target Price
www.nasdaq.com - June 27 at 4:20 PM
investorplace.com logoGo Long Valeant Pharmaceuticals Intl Inc (VRX) Stock Even After This Rip
investorplace.com - June 27 at 4:20 PM
investorplace.com logoGo Long Valeant Pharmaceuticals Intl Inc (VRX) Stock Even After this Massive Rip
investorplace.com - June 27 at 10:28 AM
News IconHedgefund Paulson & Co declares 6.3 percent stake in Valeant
www.businessinsider.com - June 26 at 9:48 PM

Social

Chart

Valeant Pharmaceuticals Intl (BVF) Chart for Wednesday, September, 20, 2017

This page was last updated on 9/20/2017 by MarketBeat.com Staff